These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 25263424)
1. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children. Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424 [TBL] [Abstract][Full Text] [Related]
2. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486 [TBL] [Abstract][Full Text] [Related]
3. Dexmedetomidine for co-analgesia in chemotherapy-induced severe enterocolitis. Winton P; Whyte E; Reimer EJ; Davis J; Whyte S Paediatr Anaesth; 2011 Sep; 21(9):980-1. PubMed ID: 21793978 [No Abstract] [Full Text] [Related]
5. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Parsons K; Bernhardt B; Strickland B Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469 [TBL] [Abstract][Full Text] [Related]
7. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma. Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742 [TBL] [Abstract][Full Text] [Related]
8. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
9. Use of dexmedetomidine in children after cardiac and thoracic surgery. Chrysostomou C; Di Filippo S; Manrique AM; Schmitt CG; Orr RA; Casta A; Suchoza E; Janosky J; Davis PJ; Munoz R Pediatr Crit Care Med; 2006 Mar; 7(2):126-31. PubMed ID: 16446599 [TBL] [Abstract][Full Text] [Related]
10. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. Siebert N; Eger C; Seidel D; Jüttner M; Lode HN J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144 [TBL] [Abstract][Full Text] [Related]
11. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM; N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881 [TBL] [Abstract][Full Text] [Related]
12. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328 [TBL] [Abstract][Full Text] [Related]
13. Multimodal Analgesic Plan for Children Undergoing Chimeric 14.18 Immunotherapy. Bertolizio G; Otis A; Tam K; Aswar S; Garbin M; Ingelmo P J Pediatr Hematol Oncol; 2021 Mar; 43(2):e169-e172. PubMed ID: 31972721 [TBL] [Abstract][Full Text] [Related]
14. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Sondel PM; Hank JA Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407 [TBL] [Abstract][Full Text] [Related]
16. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery? Chrysostomou C; Sanchez De Toledo J; Avolio T; Motoa MV; Berry D; Morell VO; Orr R; Munoz R Pediatr Crit Care Med; 2009 Nov; 10(6):654-60. PubMed ID: 19295456 [TBL] [Abstract][Full Text] [Related]
17. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]
18. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Gurbet A; Basagan-Mogol E; Turker G; Ugun F; Kaya FN; Ozcan B Can J Anaesth; 2006 Jul; 53(7):646-52. PubMed ID: 16803911 [TBL] [Abstract][Full Text] [Related]